Portuguese Registry on Acute Coronary Syndromes (ProACS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01642329|
Recruitment Status : Recruiting
First Posted : July 17, 2012
Last Update Posted : October 10, 2016
|Condition or disease|
|Acute Coronary Syndrome|
Cardiovascular diseases remain the principal causes of death in Portugal and approximately one quarter of these are directly to ischemic heart disease, especially Acute Coronary Syndromes (ACS).
In order to reduce mortality for ACS, a significant number of new drugs and new techniques have been introduced into clinical practice, resulting in important heterogeneity of approach and treatment of patients with ACS.
The Portuguese Society of Cardiology have sought to review and incorporate in its recommendations the evidence to date, with the aim to standardize diagnosis and treatment of patients with ACS, which is not always able to in daily practice.
Since it is essential to characterize the national reality of the ACS, the Portuguese Society of Cardiology has promoted the Portuguese registry on Acute Coronary Syndromes, aimed at bridging the knowledge gaps in this area of cardiovascular disease.
This will include all adult patients (≥ 18 years) diagnosed with Acute Coronary Syndrome (ACS) with <48 hours of evolution. The inclusion is of responsibility of the last service of Cardiology where the patient was hospitalized. The ACS is set to the presence of angina at rest last 48 hours, with 1) ischemic electrocardiographic changes ST-segment deviations or negative T waves, and / or 2) elevation of biomarker (cardiac troponin and CK-MB) above the reference value. For diagnosis ACS with ST elevation is considered to be persistently elevated (> 30 minutes) of the ST segment. The rest should be considered as ACS ST-segment elevation. In the absence of angina, the SCA will be considered consistent elevation (curve ascending / descending) biomarker (above reference value for cardiac troponin or higher 2 times the value of reference to the CK-MB) associated with other clinical manifestations such as ill-defined chest discomfort or dyspnea.
Are included patients participating in clinical trials
Are excluded patients with MI after revascularization procedures (EAM type 4 and 5) and MI type 2 (classification according to the redefinition of Myocardial Infarction, 2007 the Joint ESC / ACCF / AHA / WHF Task Force)
|Study Type :||Observational|
|Estimated Enrollment :||50000 participants|
|Official Title:||Portuguese Registry on Acute Coronary Syndromes|
|Study Start Date :||January 2002|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
- Hospital mortality in patients admitted for acute coronary syndrome [ Time Frame: Hospital dead in patients admitted with acute coronary syndrome ]Evaluation of hospital mortality rate of patients admitted for acute coronary syndrome
- major adverse cardiac events (MACE) [ Time Frame: In-hospital MACE in patients admitted for acute coronary syndrome ]MACE In-hospital major adverse cardiac event (death, myocardial infarction,heart failure,stroke,)
- Major bleeding [ Time Frame: In hospital major bleeding ]In Hospital major bleeding based on GUSTO definition
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642329
|Contact: Sandra M Corker, Drª||+351 239 838 firstname.lastname@example.org|
|Coimbra, Portugal, 3000-306|
|Contact: Sandra M Corker +351 239 838 101 email@example.com|
|Principal Investigator: Lino Gonçalves, Prof|
|Principal Investigator:||Jorge V Mimoso, MD||Portuguese Society of Cardiology|